AstraZeneca PLC (AZN.L)

7,709.00 +64.00 (+0.84%) As of 12:24PM GMT. Market open.

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
http://www.astrazeneca.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 70,600

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Pascal Soriot D.V.M., M.B.A.	CEO & Exec. Director	3.84M	N/A	1959
Mr. Marc Dunoyer	CFO & Exec. Director	2.02M	N/A	1952
Ms. Pam P. Cheng	Exec. Vice-Pres of Operations & Information Technology	N/A	N/A	1971
Thomas Kudsk Larsen	Head of Investor Relations	N/A	N/A	N/A
Mr. Jefrey Pott	Exec. VP of HR & Gen. Counsel	N/A	N/A	N/A
Ms. Katarina Ageborg	Exec. VP of Sustainability & Chief Compliance Officer	N/A	N/A	N/A
Dr. Menelas Pangalos	Exec. Vice-Pres of BioPharmaceuticals R&D	N/A	N/A	N/A
Dr. Ruud Dobber	Exec. Vice-Pres of BioPharmaceuticals Bus. Unit	N/A	N/A	N/A
Dr. Susan Mary Galbraith	Sr. VP and Head of Research, Early Devel. & Oncology R&D	N/A	N/A	1966
Dr. David B. Goldstein Ph.D.	Chief Adviser	N/A	N/A	N/A

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer; and Recombinetics Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Corporate governance

AstraZeneca PLC’s ISS governance QualityScore as of 1 December 2020 is 7. The pillar scores are Audit: 1; Board: 6; Shareholder rights: 10; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.